» Articles » PMID: 39554121

Antigen-specific T Cell Immunotherapy by in Vivo MRNA Delivery

Abstract

Immunotherapy has shown promise for treating patients with autoimmune diseases or cancer, yet treatment is associated with adverse effects associated with global activation or suppression of T cell immunity. Here, we developed antigen-presenting nanoparticles (APNs) to selectively engineer disease antigen (Ag)-specific T cells by mRNA delivery. APNs consist of a lipid nanoparticle core functionalized with peptide-major histocompatibility complexes (pMHCs), facilitating antigen-specific T cell transfection through cognate T cell receptor-mediated endocytosis. In mouse models of type 1 diabetes and multiple myeloma, APNs selectively deplete autoreactive T cells leading to durable control of glycemia, and engineer virus-specific T cells with anti-cancer chimeric antigen receptors (CARs), achieving comparable therapeutic outcome as virally transduced CAR. Overall, our work supports the use of APNs to engineer disease-relevant T cells as Ag-specific immunotherapy for autoimmune disorders and cancer.

References
1.
Rurik J, Tombacz I, Yadegari A, Mendez Fernandez P, Shewale S, Li L . CAR T cells produced in vivo to treat cardiac injury. Science. 2022; 375(6576):91-96. PMC: 9983611. DOI: 10.1126/science.abm0594. View

2.
Eberhardt C, Kissick H, Patel M, Cardenas M, Prokhnevska N, Obeng R . Functional HPV-specific PD-1 stem-like CD8 T cells in head and neck cancer. Nature. 2021; 597(7875):279-284. PMC: 10201342. DOI: 10.1038/s41586-021-03862-z. View

3.
Kerzel T, Giacca G, Beretta S, Bresesti C, Notaro M, Scotti G . In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases. Cancer Cell. 2023; 41(11):1892-1910.e10. DOI: 10.1016/j.ccell.2023.09.014. View

4.
Parayath N, Stephan S, Koehne A, Nelson P, Stephan M . In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020; 11(1):6080. PMC: 7695830. DOI: 10.1038/s41467-020-19486-2. View

5.
Long S, Thorpe J, DeBerg H, Gersuk V, Eddy J, Harris K . Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci Immunol. 2017; 1(5). PMC: 5486405. DOI: 10.1126/sciimmunol.aai7793. View